A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA Nephropathy
Trial details
- Registry ID
- NCT03762850
- Phase
- Phase 3
The FDA approved Dapagliflozin on 8 Jan 2014.
Drug identity checked against registry records
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Study of the Effect and Safety of Sparsentan in the Treatment of Patients With IgA NephropathyNCT03762850 | TVTX | Phase 3 | Completed | 2023-08-07Actual |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2014-01-08Day | Dapagliflozin | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "NDA202293", "applicant_as_listed_by_fda": "ASTRAZENECA AB", "brand_names": ["FARXIGA"], "active_ingredients": ["DAPAGLIFLOZIN"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20140108", "matched_on": "drug name equals FDA sole active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |